ArticleFrontiers in immunology2023
Serum cytokine and chemokine profiles and disease prognosis in hepatitis B virus-related acute-on-chronic liver failure.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- A novel nomogram based on inflammatory indexes for predicting short-term prognosis in acute-on-chronic liver failure: a comparison with classical models.European journal of medical research · 2026Article
- Serum Interleukin-8 for Differentiating Invasive Pulmonary Aspergillosis from Bacterial Pneumonia in Patients with HBV-Associated Acute-on-Chronic Liver Failure.Journal of clinical and translational hepatology · 2026Article
- Development and evaluation of a nutrient-derived anti-inflammatory dietary index (NADI) among Chinese adults.European journal of nutrition · 2026Article
- Association of nucleos(t)ide analogue treatment history with mortality in HBV-DNA-positive HBV-ACLF: a multicenter cohort study.Frontiers in immunology · 2026Article
- HBV RNA dynamics and cytokine-driven hyperinflammation: a synergistic prognostic axis in hepatitis B-related acute-on-chronic liver failure.Frontiers in cellular and infection microbiology · 2026Article
- PDK4 Regulates Inflammatory Injury in Acute-on-chronic Liver Failure by Phosphorylating STAT1-mediated M1 Polarization of Macrophages.Journal of clinical and translational hepatology · 2025Article
- Serum osteopontin levels predict short-term outcomes in patients with hepatitis B-related acute-on-chronic liver failure.Journal of virus eradication · 2025Article
- Roles of inflammatory cytokines in the pathogenesis of hepatitis B virus-related acute-on-chronic liver failure and CAR-T therapy.Virology journal · 2025Article
- Golgi protein 73 and IL-6 as strong predictors of short-term prognosis in patients with HBV-ACLF.Scientific reports · 2025Article
- Hepatitis B Virus Variants and Cytokine Patterns in Acute Liver Failure and Transplant-Free Survival.Liver international : official journal of the International Association for the Study of the Liver · 2025Observational
- Anticancer potential of eugenol in hepatocellular carcinoma through modulation of oxidative stress, inflammation, apoptosis, and proliferation mechanisms.Discover oncology · 2025Article
- Association between lactate-to-albumin ratio and mortality in hepatic failure: a retrospective cohort study.BMC infectious diseases · 2025Article
- SOCS3 and IL-6 mRNA levels in PBMC enhance the early prediction for patients with acute-on-chronic hepatitis B liver failure receiving glucocorticoid therapy.Frontiers in cellular and infection microbiology · 2025Article
- A Clinical Predictive Model Based on SOCS3 Promoter Methylation to Predict the Prognosis of Acute-on-Chronic Hepatitis B Liver Failure.Journal of inflammation research · 2025Article
- Development of a short-term prognostic model for hepatitis B-related acute-on-chronic liver failure in a dual-center cohort.Frontiers in medicine · 2025Article
- Comprehensive analysis of CXCL10 and MIP-3a reveals their potential clinical application in hepatocellular carcinoma.Translational oncology · 2024Article
- CX3CL1/Fractalkine: A Potential Biomarker for Liver Fibrosis in Chronic HBV Infection.Current issues in molecular biology · 2024Article
- The Impact of Liver Failure on the Immune System.International journal of molecular sciences · 2024Review
- Alterations in CX3CL1 Levels and Its Role in Viral Pathogenesis.International journal of molecular sciences · 2024Review
- Hepatitis B virus-related hepatocellular carcinoma exhibits distinct intratumoral microbiota and immune microenvironment signatures.Journal of medical virology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) has significant morbidity and mortality and is associated with the induction of cytokines/chemokines, which might contribute to the pathogenesis of liver injury. This study aimed to explore the cytokine/chemokine profiles of patients with HBV-ACLF and develop a composite clinical prognostic model. Methods: We prospectively collected blood samples and the clinical data of 107 patients with HBV-ACLF admitted to the Beijing Ditan Hospital. The concentrations of 40-plex cytokines/chemokines were measured in 86 survivors and 21 non-survivors using the Luminex assay. Discrimination between the cytokine/chemokine profiles in different prognosis groups was analyzed using the multivariate statistical techniques of principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA). An immune-clinical prognostic model was obtained using multivariate logistic regression analysis. Results: The PCA and PLS-DA indicated that cytokine/chemokine profiling could clearly distinguish patients with different prognoses. A total of 14 cytokines, namely, IL-1β, IL-6, IL-8, IL-10, TNF-α, IFN-γ, CXCL1, CXCL2, CXCL9, CXCL13, CX3CL1, GM-SCF, CCL21, and CCL23, were significantly correlated with disease prognosis. Multivariate analysis identified CXCL2, IL-8, total bilirubin, and age as independent risk factors that constituted the immune-clinical prognostic model, which showed the strongest predictive value of 0.938 compared with those of the Chronic Liver Failure Consortium (CLIF-C) ACLF (0.785), Model for End-Stage Liver Disease (MELD) (0.669), and MELD-Na (0.723) scores ( Conclusion: The serum cytokine/chemokine profiles correlated with the 90-day prognosis of patients with HBV-ACLF. The proposed composite immune-clinical prognostic model resulted in more accurate prognostic estimates than those of the CLIF-C ACLF, MELD, and MELD-Na scores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.